Tags

Type your tag names separated by a space and hit enter

Two-year randomized, placebo-controlled study of black currant anthocyanins on visual field in glaucoma.
Ophthalmologica 2012; 228(1):26-35O

Abstract

AIM

To examine the influence of the black currant anthocyanins (BCACs) on the disease progression of open-angle glaucoma (OAG), a randomized, placebo-controlled, double-masked trial was made in 38 patients with OAG treated by antiglaucoma drops.

METHODS

BCACs (50 mg/day, n = 19) or their placebos (n = 19) were orally administered once daily for a 24-month period. Systemic blood pressure, pulse rates, intraocular pressure (IOP), ocular blood circulation by laser-speckle flowgraphy, and Humphrey visual field mean deviation (MD) were measured during the 24-month period.

RESULTS

As a main outcome measurement, we evaluated the difference between the groups in MD deterioration in the eye with a better MD from the trial's baseline through 24 months. A statistically significant difference was observed between the treatment groups in mean change from baseline in MD 24 months after therapy (p = 0.039, unpaired t test). Upon administration of BCACs, the ocular blood flows during the 24-month observational period increased in comparison with placebo-treated patients. However, no significant changes were observed in systemic and ocular conditions including IOP during the 24-month period.

CONCLUSIONS

Our results suggest that oral administration of BCACs may be a safe and promising supplement for patients with OAG in addition to antiglaucoma medication.

Authors+Show Affiliations

Department of Ophthalmology, Sapporo Medical University School of Medicine, Sapporo, Japan. ooguro @ sapmed.ac.jp

Pub Type(s)

Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

22377796

Citation

Ohguro, Hiroshi, et al. "Two-year Randomized, Placebo-controlled Study of Black Currant Anthocyanins On Visual Field in Glaucoma." Ophthalmologica. Journal International D'ophtalmologie. International Journal of Ophthalmology. Zeitschrift Fur Augenheilkunde, vol. 228, no. 1, 2012, pp. 26-35.
Ohguro H, Ohguro I, Katai M, et al. Two-year randomized, placebo-controlled study of black currant anthocyanins on visual field in glaucoma. Ophthalmologica. 2012;228(1):26-35.
Ohguro, H., Ohguro, I., Katai, M., & Tanaka, S. (2012). Two-year randomized, placebo-controlled study of black currant anthocyanins on visual field in glaucoma. Ophthalmologica. Journal International D'ophtalmologie. International Journal of Ophthalmology. Zeitschrift Fur Augenheilkunde, 228(1), pp. 26-35. doi:10.1159/000335961.
Ohguro H, et al. Two-year Randomized, Placebo-controlled Study of Black Currant Anthocyanins On Visual Field in Glaucoma. Ophthalmologica. 2012;228(1):26-35. PubMed PMID: 22377796.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Two-year randomized, placebo-controlled study of black currant anthocyanins on visual field in glaucoma. AU - Ohguro,Hiroshi, AU - Ohguro,Ikuyo, AU - Katai,Maki, AU - Tanaka,Sachie, Y1 - 2012/02/22/ PY - 2011/10/06/received PY - 2011/12/11/accepted PY - 2012/3/2/entrez PY - 2012/3/2/pubmed PY - 2012/9/29/medline SP - 26 EP - 35 JF - Ophthalmologica. Journal international d'ophtalmologie. International journal of ophthalmology. Zeitschrift fur Augenheilkunde JO - Ophthalmologica VL - 228 IS - 1 N2 - AIM: To examine the influence of the black currant anthocyanins (BCACs) on the disease progression of open-angle glaucoma (OAG), a randomized, placebo-controlled, double-masked trial was made in 38 patients with OAG treated by antiglaucoma drops. METHODS: BCACs (50 mg/day, n = 19) or their placebos (n = 19) were orally administered once daily for a 24-month period. Systemic blood pressure, pulse rates, intraocular pressure (IOP), ocular blood circulation by laser-speckle flowgraphy, and Humphrey visual field mean deviation (MD) were measured during the 24-month period. RESULTS: As a main outcome measurement, we evaluated the difference between the groups in MD deterioration in the eye with a better MD from the trial's baseline through 24 months. A statistically significant difference was observed between the treatment groups in mean change from baseline in MD 24 months after therapy (p = 0.039, unpaired t test). Upon administration of BCACs, the ocular blood flows during the 24-month observational period increased in comparison with placebo-treated patients. However, no significant changes were observed in systemic and ocular conditions including IOP during the 24-month period. CONCLUSIONS: Our results suggest that oral administration of BCACs may be a safe and promising supplement for patients with OAG in addition to antiglaucoma medication. SN - 1423-0267 UR - https://www.unboundmedicine.com/medline/citation/22377796/Two_year_randomized_placebo_controlled_study_of_black_currant_anthocyanins_on_visual_field_in_glaucoma_ L2 - https://www.karger.com?DOI=10.1159/000335961 DB - PRIME DP - Unbound Medicine ER -